All In MedTech

FDA Clearance Tracker · P150033-S161

Micra VR2 Transcatheter Pacing System, Micra AV2 Transcatheter Pacing System, Micra VR2/AV2 Application Software

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 20, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 20, 2023

Approved

Time to decision

167 days

Received Nov 4, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150033-S161
Device name
Micra VR2 Transcatheter Pacing System, Micra AV2 Transcatheter Pacing System, Micra VR2/AV2 Application Software
Applicant location
Mounds View, MN
Received
Nov 4, 2022
Decided
Apr 20, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150033

Device type

Device class
Class III
Regulation
21 CFR 870.3610

Every decision under product code PNJ

FDA's approval statement

As written in FDA's record.

Approval for two new models in the Micra Transcatheter Pacing System family, the Micra VR2 and the Micra AV2.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.